華潤醫藥(03320.HK)擬成立合資創新投資基金
華潤醫藥(03320.HK)宣布,華潤醫藥(成都)企業管理合夥企業、公司全資附屬公司華潤醫藥投資有限公司、非全資附屬華潤博雅生物(300294.SZ)、非全資附屬東阿阿膠(000423.SZ)、非全資附屬華潤雙鶴(600062.SH)、非全資附屬江中藥業(600750.SH)、成都潤藥產業投資合夥企業,以及五名其他獨立第三方擬就成立合資基金「華潤醫藥(成都)創新投資基金合夥企業(暫命名)」訂立協議,擬議規模為10億元人民幣,總年期為七年。
集團的擬議資承擔總額將約為2.45億元,佔基金資本承擔總額約24.5%。預期基金成立後將不會入賬列作公司的附屬公司。預期深圳市華潤資本股權投資有限公司將受託擔任基金的基金管理人。
公告續指,預期基金將主要從事股權投資、創業資本及投資管理活動,主要投資醫藥及健康產業以及戰略性新興領域。考慮到成都政府的產業政策及優惠措施,預期基金將重點投資於化學創新藥、生物藥(包括疫苗)、高端醫療器械(包括IVD)、中藥滋補品類、合成生物等領域的企業以及其他戰略性新興領域的企業。
擬議成立基金須待簽立有限合夥協議及當中所載的各項條件後,方可作實,且未必會進行。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.